Overview

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

Status:
Unknown status

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.

Phase:

Phase 4

Details

Lead Sponsor:

Núcleo de Estudos em Esportes e Ortopedia, Brazil

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Anti-Inflammatory Agents, Non-Steroidal
Etoricoxib